Bicara Therapeutics sees cash runway into 1H29

As of December 31, 2024, Bicara had cash and cash equivalents of $489.7M, compared to $230.4M as of December 31, 2023. Based on its current operating and development plans, the Company expects that its existing cash and cash equivalents will fund operations into the first half of 2029.